Dr PREVOST Alain

Fiche personne


coordonnées

Institut Jean Godinot
1 rue du Général Koenig
51726 REIMS Cedex

03 26 50 44 26

alain.prevost@reims.unicancer.fr

Territoire

Champagne-Ardenne

Statut

Hospitalier

Recherche

Expertises :
- Clinique:Pneumologie
- Cancer:Poumon

Publications


Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F,

Cancer Radiother. 2022 Mar 5;:

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.

Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S

ESMO Open. 2022 Feb 25;7(2):100418

18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.

Dejust S, Moubtakir A, Prevost A, El Farsaoui K, Morland D

Clin Nucl Med. 2020 Jan 17;:

Voir plus